These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 30478067)
1. Ticagrelor for Refractory Migraine/Patent Foramen Ovale (TRACTOR): An open-label pilot study. Reisman AM; Robbins BT; Chou DE; Yugrakh MS; Gross GJ; Privitera L; Nazif T; Sommer RJ Neurology; 2018 Nov; 91(22):1010-1017. PubMed ID: 30478067 [TBL] [Abstract][Full Text] [Related]
2. Retrospective review of thienopyridine therapy in migraineurs with patent foramen ovale. Sommer RJ; Nazif T; Privitera L; Robbins BT Neurology; 2018 Nov; 91(22):1002-1009. PubMed ID: 30478066 [TBL] [Abstract][Full Text] [Related]
3. A retrospective review of clopidogrel as primary therapy for migraineurs with right to left shunt lesions. Spencer BT; Qureshi Y; Sommer RJ Cephalalgia; 2014 Oct; 34(11):933-7. PubMed ID: 24770421 [TBL] [Abstract][Full Text] [Related]
4. Clopidogrel can be an effective complementary prophylactic for drug-refractory migraine with patent foramen ovale. Guo Y; Shi Y; Zhu D; Liu R; Qi Y; Luo G J Investig Med; 2020 Oct; 68(7):1250-1255. PubMed ID: 32848048 [TBL] [Abstract][Full Text] [Related]
5. Incidence, timing, and predictive factors of new-onset migraine headache attack after transcatheter closure of atrial septal defect or patent foramen ovale. Rodés-Cabau J; Mineau S; Marrero A; Houde C; Mackey A; Côté JM; Chetaille P; Delisle G; Bertrand OF; Rivest D Am J Cardiol; 2008 Mar; 101(5):688-92. PubMed ID: 18308022 [TBL] [Abstract][Full Text] [Related]
6. Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial. Mattle HP; Evers S; Hildick-Smith D; Becker WJ; Baumgartner H; Chataway J; Gawel M; Göbel H; Heinze A; Horlick E; Malik I; Ray S; Zermansky A; Findling O; Windecker S; Meier B Eur Heart J; 2016 Jul; 37(26):2029-36. PubMed ID: 26908949 [TBL] [Abstract][Full Text] [Related]
7. Percutaneous Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM Trial. Tobis JM; Charles A; Silberstein SD; Sorensen S; Maini B; Horwitz PA; Gurley JC J Am Coll Cardiol; 2017 Dec; 70(22):2766-2774. PubMed ID: 29191325 [TBL] [Abstract][Full Text] [Related]
9. Usefulness of transcatheter patent foramen ovale closure in migraineurs with moderate to large right-to-left shunt and instrumental evidence of cerebrovascular damage. Papa M; Gaspardone A; Fragasso G; Ajello S; Gioffrè G; Iamele M; Iani C; Margonato A Am J Cardiol; 2009 Aug; 104(3):434-9. PubMed ID: 19616680 [TBL] [Abstract][Full Text] [Related]
10. Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Dowson A; Mullen MJ; Peatfield R; Muir K; Khan AA; Wells C; Lipscombe SL; Rees T; De Giovanni JV; Morrison WL; Hildick-Smith D; Elrington G; Hillis WS; Malik IS; Rickards A Circulation; 2008 Mar; 117(11):1397-404. PubMed ID: 18316488 [TBL] [Abstract][Full Text] [Related]
11. Frequency of migraine headache relief following patent foramen ovale "closure" despite residual right-to-left shunt. Jesurum JT; Fuller CJ; Kim CJ; Krabill KA; Spencer MP; Olsen JV; Likosky WH; Reisman M Am J Cardiol; 2008 Oct; 102(7):916-20. PubMed ID: 18805122 [TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of randomized trials on percutaneous patent foramen ovale closure for prevention of migraine. Elbadawi A; Barssoum K; Abuzaid AS; Rezq A; Biniwale N; Alotaki E; Mohamed AH; Vuyyala S; Ogunbayo GO; Saad M Acta Cardiol; 2019 Apr; 74(2):124-129. PubMed ID: 29914296 [TBL] [Abstract][Full Text] [Related]
13. Platelet P2Y12 Inhibitor in the Treatment and Prevention of Migraine: A Systematic Review and Meta-Analysis. Wang F; Cao Y; Liu Y; Ren Z; Li F Behav Neurol; 2022; 2022():2118740. PubMed ID: 35355664 [TBL] [Abstract][Full Text] [Related]
15. Improvement of migraine headaches after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism. Wahl A; Praz F; Tai T; Findling O; Walpoth N; Nedeltchev K; Schwerzmann M; Windecker S; Mattle HP; Meier B Heart; 2010 Jun; 96(12):967-73. PubMed ID: 20538672 [TBL] [Abstract][Full Text] [Related]
16. Impact of transcatheter closure of patent foramen ovale in the evolution of migraine and role of residual shunt. Biasco L; Infantino V; Orzan F; Vicentini S; Rovera C; Longo G; Chinaglia A; Belli R; Allais G; Gaita F J Cardiol; 2014 Nov; 64(5):390-4. PubMed ID: 24713153 [TBL] [Abstract][Full Text] [Related]
17. Association of interatrial shunts and migraine headaches: impact of transcatheter closure. Azarbal B; Tobis J; Suh W; Chan V; Dao C; Gaster R J Am Coll Cardiol; 2005 Feb; 45(4):489-92. PubMed ID: 15708691 [TBL] [Abstract][Full Text] [Related]
18. Spontaneous large right-to-left shunt and migraine headache with aura are risk factors for recurrent stroke in patients with a patent foramen ovale. Giardini A; Donti A; Formigari R; Salomone L; Palareti G; Guidetti D; Picchio FM Int J Cardiol; 2007 Sep; 120(3):357-62. PubMed ID: 17166607 [TBL] [Abstract][Full Text] [Related]
19. Calcitonin gene-related peptide: a possible biomarker in migraine patients with patent foramen ovale. Li C; Yu Y; Li N; Yin YN; Zhang L; Xie K; Huang D BMC Neurol; 2024 Apr; 24(1):126. PubMed ID: 38627623 [TBL] [Abstract][Full Text] [Related]
20. Prevalence of Right to Left Shunts in Japanese Patients with Migraine: A Single-center Study. Iwasaki A; Suzuki K; Takekawa H; Takashima R; Suzuki A; Suzuki S; Hirata K Intern Med; 2017; 56(12):1491-1495. PubMed ID: 28626173 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]